3 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
Follow Pseudomyxoma Peritonei: new trials by email Literature Review of Pseudomyxoma Peritonei trials Research Report on Pseudomyxoma Peritonei
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms Metformin - Appendiceal Mucinous Neoplasm, Pseudomyxoma Peritonei | Phase 2 | Recruiting | University of California, Irvine | 15 | 2026-06-18 | 2026-07-13 |
| Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day - Pseudomyxoma Peritonei | Phase 2 | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 31 | 2024-11-22 | 2025-01-30 |
| Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC Mitomycin C, flat dose 40 mg, Mitomycin C, weight-based dose 12.5 mg/m2 - Peritoneal Carcinomatosis | Phase 2 | Recruiting | Prakash Pandalai | 100 | 2021-06-04 | 2026-04-01 |
Appendiceal Neoplasms (1) · Colorectal Neoplasms (1) · Peritoneal Neoplasms (1)
Adenocarcinoma (3) · Adenocarcinoma, Mucinous (3) · Carcinoma (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Cystic, Mucinous, and Serous (3) · Neoplasms, Glandular and Epithelial (3) · Abdominal Neoplasms (1) · Cecal Diseases (1) · Cecal Neoplasms (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1)
Capecitabine (1) · Metformin (1) · Mitomycin (1)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Prakash Pandalai (1) · University of California, Irvine (1)
United States (2) · Italy (1)
Alessandra Raimondi, MD (1) · Oliver Eng, MD (1) · Prakash Pandalai, MD (1)